News • T2Resistance Panel

Rapid diagnosis of bacterial infections

T2 Biosystems and CARB-X announced that the T2Resistance Panel is the first diagnostic to graduate from CARB-X’s portfolio. The graduation marks an important milestone on the path toward approval for use on patients in hospitals in the U.S., Europe and elsewhere around the globe.

Photo

The T2Resistance Panel is designed to detect 13 resistance genes from both gram-positive and gram-negative pathogens directly from a whole-blood specimen, without the need to wait for blood cultures. The panel is expected to be available for research use only (RUO) in the U.S. by the end of Q3 2019 and receive CE-Mark for commercial availability in Europe by the end of 2019.

“Addressing the global superbug crisis requires urgent development of innovative diagnostics, like T2’s technology, as well as new drugs and vaccines. This is the first diagnostic to graduate from CARB-X’s portfolio, and we are excited that we could help T2 with funding and support to develop this technology,” said Kevin Outterson, Executive Director of CARB-X, which is based at the Boston University School of Law. “The T2Resistance Panel will provide healthcare professionals with a new rapid test, a first of its kind, to provide timely and accurate detection of drug-resistant infections and inform treatment decisions to ensure patients are given the most appropriate care.”

“Rapid identification of the genes and species associated with antibiotic resistance can help enable the reduction of unnecessary antibiotic use, which is the primary cause of resistance. Being the first diagnostic to graduate from CARB-X’s portfolio is a significant milestone in the development of technology that has such capabilities,” said John McDonough, chairman and chief executive officer of T2 Biosystems.

Recommended article

The T2Resistance Panel identifies 13 of the most serious superbugs and resistance genes on the antibiotic-resistance threat list published by the Centers for Disease Control and Prevention (CDC), including genes indicating resistance to common empiric antibiotic therapies such as carbapenems, vancomycin, penicillin and more.

Photo

Diagnosing infections faster means saving lives and fighting the spread of superbugs

Bacterial bloodstream infections can be deadly even at low concentrations. If bacterial infections are identified quickly, patients can be placed on effective antibiotic therapy faster. T2MR technology enables rapid identification of bacterial pathogens and resistance markers directly in whole blood within three to five hours. Existing diagnostics rely primarily on blood cultures conducted in laboratories, which can take days, and do not always produce reliable results. As a result, physicians are often unable to treat infections quickly with the appropriate antibiotics, leading to higher mortality and use of unnecessary antibiotics.

Source: T2 Biosystems

25.09.2019

Read all latest stories

Related articles

Photo

News • MRSA

Decolonization protocol can prevent dangerous infections

Antiseptic soap, mouthwash, and nose ointment after hospital discharge reduced infections and infection-associated hospitalizations due to MRSA in high-risk patients. Hospital patients who have…

Photo

News • Scientific breakthrough

New accelerated diagnosis of multi-resistant hospital pathogens

A team of researchers at the University of Cologne's Faculty of Medicine and the German Center for Infection Research (DZIF) use a novel immunochromatographic method to detect bacteria that are…

Photo

News • Direct from whole blood samples

LiDia demonstrates rapid and sensitive BSI identification

DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new, game-changing test for bloodstream infections that can lead to sepsis announced new data on its…

Related products

Siemens Healthineers – Fast Track Real-time PCR assays

Infectious Disease

Siemens Healthineers – Fast Track Real-time PCR assays

Siemens Healthineers
Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Greiner – Vacuette CAT Serum Fast Tube

Clinical Chemistry

Greiner – Vacuette CAT Serum Fast Tube

Greiner Bio-One
Subscribe to Newsletter